Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 5,349 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The stock was purchased at an average price of $19.85 per share, with a total value of $106,177.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Xencor, Inc. (NASDAQ XNCR) traded up $0.01 during trading hours on Thursday, reaching $22.26. The company had a trading volume of 144,848 shares, compared to its average volume of 215,764. Xencor, Inc. has a 1 year low of $18.55 and a 1 year high of $28.64.
A number of institutional investors have recently bought and sold shares of the business. FMR LLC grew its position in Xencor by 77.7% during the 2nd quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after purchasing an additional 2,924,510 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Xencor by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after buying an additional 90,094 shares during the period. State Street Corp boosted its stake in shares of Xencor by 11.1% during the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock valued at $23,295,000 after buying an additional 110,474 shares during the period. Northern Trust Corp boosted its stake in shares of Xencor by 6.6% during the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock valued at $10,527,000 after buying an additional 30,715 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Xencor by 8.0% during the 1st quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock valued at $8,783,000 after buying an additional 27,099 shares during the period. Hedge funds and other institutional investors own 77.62% of the company’s stock.
A number of equities analysts recently commented on XNCR shares. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 target price on shares of Xencor in a report on Sunday, November 12th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Xencor has a consensus rating of “Hold” and a consensus price target of $30.80.
COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (NASDAQ:XNCR) Major Shareholder Acquires $106,177.65 in Stock” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thelincolnianonline.com/2017/12/07/xencor-inc-xncr-major-shareholder-purchases-106177-65-in-stock-updated.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.